These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 25363327)

  • 61. [Long-term viral response to interferon alpha 2b plus ribavirin in chronic hepatitis C patients during standard therapy].
    Adamek A; Adamek J; Juszczyk J; Bereszyńska I
    Przegl Epidemiol; 2007; 61(4):765-70. PubMed ID: 18572509
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Alpha interferon therapy of chronic delta hepatitis: a pilot study.
    Di Bisceglie AM; Negro F; Smedile A; Bergmann K; Hoofnagle JH
    Prog Clin Biol Res; 1991; 364():393-7. PubMed ID: 2020714
    [No Abstract]   [Full Text] [Related]  

  • 63. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
    Chen LW; Chien RN; Yen CL; Chang JJ; Liu CJ; Lin CL
    J Gastroenterol Hepatol; 2010 Feb; 25(2):259-63. PubMed ID: 19817959
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B?
    Janssen HL; Sonneveld MJ; Brunetto MR
    Gut; 2012 May; 61(5):641-5. PubMed ID: 22180061
    [No Abstract]   [Full Text] [Related]  

  • 65. Boosting of Hepatitis B Virus-Specific T Cell Responses After Pegylated-Interferon-α-2a Therapy for Hepatitis B e Antigen-Positive Pediatric Patients.
    Ning L; Huang X; Xu Y; Yang G; Yang J; Fu Q; Zhang Q; Liu H; Wu X; Wang Z; Luo K
    J Interferon Cytokine Res; 2019 Dec; 39(12):740-751. PubMed ID: 31329012
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy).
    Halfon P; Pérusat S; Bourlière M; Bronowicki JP; Trimoulet P; Benhamou Y; Leroy V; Marcellin P; Foucher J; Penaranda G; Chêne G; Couzigou P;
    J Med Virol; 2010 Dec; 82(12):2027-31. PubMed ID: 20981789
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Pegylated interferons: pharmacological basis].
    Macquin-Mavier I; Hezode C; Dhumeaux D
    Gastroenterol Clin Biol; 2002; 26(8-9):742-7. PubMed ID: 12434079
    [No Abstract]   [Full Text] [Related]  

  • 68. HBV/HDV Coinfection: A Challenge for Therapeutics.
    Koh C; Da BL; Glenn JS
    Clin Liver Dis; 2019 Aug; 23(3):557-572. PubMed ID: 31266627
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Interferon therapy for chronic hepatitis B.
    Asselah T; Lada O; Moucari R; Martinot M; Boyer N; Marcellin P
    Clin Liver Dis; 2007 Nov; 11(4):839-49, viii. PubMed ID: 17981231
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Chronic Hepatitis D; at a Standstill?
    Rizzetto M
    Dig Dis; 2016; 34(4):303-7. PubMed ID: 27170382
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Resistance of hepatitis delta virus replication to interferon-alpha treatment in transfected human cells.
    Ilan Y; Klein A; Taylor J; Tur-Kaspa R
    J Infect Dis; 1992 Nov; 166(5):1164-6. PubMed ID: 1328404
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta.
    Niro GA; Ciancio A; Gaeta GB; Smedile A; Marrone A; Olivero A; Stanzione M; David E; Brancaccio G; Fontana R; Perri F; Andriulli A; Rizzetto M
    Hepatology; 2006 Sep; 44(3):713-20. PubMed ID: 16941685
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Modelling hepatitis C virus kinetics during treatment with pegylated interferon alpha-2b: errors in the estimation of viral kinetic parameters.
    Shudo E; Ribeiro RM; Perelson AS
    J Viral Hepat; 2008 May; 15(5):357-62. PubMed ID: 18380660
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg.
    Shekhtman L; Cotler SJ; Hershkovich L; Uprichard SL; Bazinet M; Pantea V; Cebotarescu V; Cojuhari L; Jimbei P; Krawczyk A; Dittmer U; Vaillant A; Dahari H
    Sci Rep; 2020 May; 10(1):7837. PubMed ID: 32398799
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Neutralizing antibodies to interferon alpha in a chronic hepatitis C patient non-responder to pegylated interferon.
    Santantonio T; Milella M; Antonelli G; Scagnolari C
    J Hepatol; 2006 Nov; 45(5):759-61. PubMed ID: 16979777
    [No Abstract]   [Full Text] [Related]  

  • 76. From genetic association studies to the biology of interleukin-28B in hepatitis C virus infection and beyond.
    Lange CM
    Gut; 2013 Sep; 62(9):1246-7. PubMed ID: 23263526
    [No Abstract]   [Full Text] [Related]  

  • 77. Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype.
    Huang CF; Yu ML; Kao JH; Tseng TC; Yeh ML; Huang JF; Dai CY; Lin ZY; Chen SC; Wang LY; Juo SH; Chuang WL; Liu CH
    J Clin Virol; 2013 Apr; 56(4):293-8. PubMed ID: 23246359
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication.
    Lutgehetmann M; Volzt T; Quaas A; Zankel M; Fischer C; Dandri M; Petersen J
    Antivir Ther; 2008; 13(1):57-66. PubMed ID: 18389899
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
    Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V
    Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
    [TBL] [Abstract][Full Text] [Related]  

  • 80. CD56
    Shi A; Zhang X; Xiao F; Zhu L; Yan W; Han M; Luo X; Chen T; Ning Q
    J Viral Hepat; 2018 Nov; 25(11):1352-1362. PubMed ID: 29888839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.